These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 31822364)

  • 1. CMIP promotes Herceptin resistance of HER2 positive gastric cancer cells.
    Xiang R; Han X; Ding K; Wu Z
    Pathol Res Pract; 2020 Feb; 216(2):152776. PubMed ID: 31822364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of GSE1 Related to Trastuzumab Resistance in Gastric Cancer Cells.
    Wang W; Wang S; Xu AM; Yuan X; Huang L; Li J
    Biomed Res Int; 2021; 2021():8834923. PubMed ID: 33623790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
    Chen YC; Li HY; Liang JL; Ger LP; Chang HT; Hsiao M; Calkins MJ; Cheng HC; Chuang JH; Lu PJ
    Oncotarget; 2017 May; 8(18):29699-29710. PubMed ID: 27447863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YAP inhibition overcomes adaptive resistance in HER2-positive gastric cancer treated with trastuzumab via the AKT/mTOR and ERK/mTOR axis.
    Qiao J; Feng M; Zhou W; Tan Y; Yang S; Liu Q; Wang Q; Feng W; Pan Y; Cui L
    Gastric Cancer; 2024 Jul; 27(4):785-801. PubMed ID: 38782859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition.
    Jin MH; Nam AR; Park JE; Bang JH; Bang YJ; Oh DY
    Mol Cancer Ther; 2017 Jun; 16(6):1145-1154. PubMed ID: 28223426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CMIP is oncogenic in human gastric cancer cells.
    Zhang J; Huang J; Wang X; Chen W; Tang Q; Fang M; Qian Y
    Mol Med Rep; 2017 Nov; 16(5):7277-7286. PubMed ID: 28944848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-98-5p/IGF2 Axis Influence Herceptin Sensitivity through IGF1R/HER2 Heterodimer Formation and AKT/mTOR Signal Pathway in HER2 Positive Breast Cancer.
    Zhang M; Li Z; Liu X
    Asian Pac J Cancer Prev; 2021 Nov; 22(11):3693-3703. PubMed ID: 34837929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
    Saeki H; Oki E; Kashiwada T; Arigami T; Makiyama A; Iwatsuki M; Narita Y; Satake H; Matsuda Y; Sonoda H; Shimokawa M; Maehara Y;
    Eur J Cancer; 2018 Dec; 105():41-49. PubMed ID: 30391779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.
    Piro G; Carbone C; Cataldo I; Di Nicolantonio F; Giacopuzzi S; Aprile G; Simionato F; Boschi F; Zanotto M; Mina MM; Santoro R; Merz V; Sbarbati A; de Manzoni G; Scarpa A; Tortora G; Melisi D
    Clin Cancer Res; 2016 Dec; 22(24):6164-6175. PubMed ID: 27267856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Label-Free Quantitative Proteomics Combined with Biological Validation Reveals Activation of Wnt/β-Catenin Pathway Contributing to Trastuzumab Resistance in Gastric Cancer.
    Liu W; Yuan J; Liu Z; Zhang J; Chang J
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29986466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer.
    Shi W; Zhang G; Ma Z; Li L; Liu M; Qin L; Yu Z; Zhao L; Liu Y; Zhang X; Qin J; Ye H; Jiang X; Zhou H; Sun H; Jiao Z
    Nat Commun; 2021 May; 12(1):2812. PubMed ID: 33990570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolomic therapy response prediction in pretherapeutic tissue biopsies for trastuzumab in patients with HER2-positive advanced gastric cancer.
    Kunzke T; Hölzl FT; Prade VM; Buck A; Huber K; Feuchtinger A; Ebert K; Zwingenberger G; Geffers R; Hauck SM; Haffner I; Luber B; Lordick F; Walch A
    Clin Transl Med; 2021 Sep; 11(9):e547. PubMed ID: 34586736
    [No Abstract]   [Full Text] [Related]  

  • 13. DNA Methylation-Regulated HOXC8's Role in HER2-Positive Breast Cancer Function and its Contribution to Herceptin Resistance.
    Xie X; Tang S; Yu Z
    Discov Med; 2024 Mar; 36(182):559-570. PubMed ID: 38531796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultrasound Microbubbles Mediated Sonosensitizer and Antibody Co-delivery for Highly Efficient Synergistic Therapy on HER2-Positive Gastric Cancer.
    Sun L; Zhang J; Xu M; Zhang L; Tang Q; Chen J; Gong M; Sun S; Ge H; Wang S; Liang X; Cui L
    ACS Appl Mater Interfaces; 2022 Jan; 14(1):452-463. PubMed ID: 34961307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
    Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L
    BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer.
    Arienti C; Zanoni M; Pignatta S; Del Rio A; Carloni S; Tebaldi M; Tedaldi G; Tesei A
    Oncotarget; 2016 Apr; 7(14):18424-39. PubMed ID: 26919099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.
    Pietrantonio F; Fucà G; Morano F; Gloghini A; Corso S; Aprile G; Perrone F; De Vita F; Tamborini E; Tomasello G; Gualeni AV; Ongaro E; Busico A; Giommoni E; Volpi CC; Laterza MM; Corallo S; Prisciandaro M; Antista M; Pellegrinelli A; Castagnoli L; Pupa SM; Pruneri G; de Braud F; Giordano S; Cremolini C; Di Bartolomeo M
    Clin Cancer Res; 2018 Mar; 24(5):1082-1089. PubMed ID: 29208673
    [No Abstract]   [Full Text] [Related]  

  • 18. ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer.
    Barok M; Le Joncour V; Martins A; Isola J; Salmikangas M; Laakkonen P; Joensuu H
    Cancer Lett; 2020 Mar; 473():156-163. PubMed ID: 31904483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptome and chromatin landscape changes associated with trastuzumab resistance in HER2+ breast cancer cells.
    Murad R; Avanes A; Ma X; Geng S; Mortazavi A; Momand J
    Gene; 2021 Oct; 799():145808. PubMed ID: 34224831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
    Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
    Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.